Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.63 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.57 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595370 | 1.00 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL3587909 | 1.00 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL3591112 | 0.97 | CHRM1 (0.65) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL3599215 | 0.93 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL3583488 | 0.87 | POLB (0.60) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL3590307 | 0.87 | CHRM1 (0.56) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL3585649 | 0.87 | CHRM1 (0.56) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL3596759 | 0.87 | POLB (0.60) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL27056698 | 0.87 | OPRL1 (0.61) | CHRM1CHRM2CHRM4CHRM3SLC18A3 | |
| SCHEMBL3595998 | 0.87 | OPRL1 (0.61) | CHRM1CHRM2CHRM4CHRM3SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2128154-B1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-04-08 | — | — | EP | disclosed |
| EP-2128154-B1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8877779-B2 | Benzimidazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| US-8877779-B2 | Benzimidazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| US-8877779-B2 | Benzimidazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2128154-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | ORMDL3, OXA1L, OGFRL1 | CHRM1 300/4885CHRM2 722/4885CHRM4 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.